Squamous cell carcinoma of the lung is associated with smoking in its development and com prises about 20-30% of all lung cancers. Treatment development for squamous cell carcinoma of the lung was gen erally stagnant for several years. However, in the 2010s, several clinical trials showing the efficacy of immune checkpoint inhibitors or chemotherapy such as nedaplatin combination have been reported, and the number o treatment options has significantly increased. In addition, new evidence, such as findings supporting combination therapy of chemotherapy and immune checkpoint inhibitors, is being accumulated. In this review, we will de scribe various clinical studies mainly involving non-elderly patients with a good performance status. In addition we will present the results of clinical trials newly reported in 2018.
- Cytotoxic (anticancer) drug
- Immune checkpoint inhibitor
- Squamous cell carcinoma of the lung
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine